OTLC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 02:37):

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications...

Stats
今日成交量	21 310.00
平均成交量	76 704.00
市值	15.75M
EPS	$0 ( 2024-04-12 )
下一个收益日期	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-29	Trieu Vuong	Buy	425 000	Common Stock
2023-06-28	Trieu Vuong	Buy	75 000	Common Stock
2023-06-16	Trieu Vuong	Buy	100 000	Common Stock
2023-06-14	Trieu Vuong	Buy	400 000	Common Stock
2023-05-26	Trieu Vuong	Buy	126 888	Common Stock

INSIDER POWER
100.00
Last 94 transactions
Buy: 129 604 070 \| Sell: 133 128 556

Oncotelic Therapeutics, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Oncotelic Therapeutics, 财务报表

Annual	2023
营收:	$70 000.00
毛利润:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2023
营收:	$70 000.00
毛利润:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2022
营收:	$0
毛利润:	$-12 841.00 (0.00 %)
EPS:	$0.0464

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Oncotelic Therapeutics,

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.